This approach can also be used to verify blood markers identified in patients at the clinical stage of PD. It is also evident that the complex socioeconomic factors influencing the incidence of PD is different in developed versus developing countries. The societal and medical costs of Parkinson’s are huge and efforts to improve early preclinical […]
We provide converging evidence from observational analyses in UKB and MR that lower lymphocyte count is associated with an increased risk of subsequent PD. CLICK TO REVIEW
Lower lymphocyte count is associated with increased risk of Parkinson’s disease Read More »
Parkinson’s disease is predominantly classified as a movement disorder. Beyond the textbook definition of rigidity, tremors, and bradykinesia, Parkinson’s disease encompasses an entire entity of non-motor symptom complexes that can precede the motor features by many years. Despite their significant clinical importance, the awareness of non-motor symptoms is quite negligible. Sleep disorders, gastrointestinal dysfunction, olfactory
Spectrum of Non-Motor Symptoms in Parkinson’s Disease Read More »
A simple eye exam combined with powerful artificial intelligence (AI) machine learning technology could provide early detection of Parkinson’s disease, according to research being presented at the annual meeting of the Radiological Society of North America (RSNA). CLICK TO REVIEW
Eye Exam Could Lead to Early Parkinson’s Disease Diagnosis Read More »
Conclusion The whole thickness, the thickness of the combination of ganglion cell layer and inner plexiform layer, and nervefiber layer of central retina decreased significantly in PD patients. CLICK TO REVIEW
Central retina changes in Parkinson’s disease: a systematic review and meta‑analysis Read More »
The frequencies of symptoms and abnormal findings in PD patients were as follows: hyposmia 82.4%, substantia nigra hyperechogenicity 75.4%, history of anxiety or depression disorder 29.5%, constipation 22.1%, and REM (rapid eye movement) sleep behavior disorder 22%. Conclusion: Baseline characteristics of patients enrolled in the BIO-PD study are comparable to other de novo PD cohorts,
Olfactory impairment has been considered for differential diagnosis in Parkinson’s Disease (PD) patients. The authors aimed to identify the tests used to assess the olfactory function in PD patients and examine these tests’ ability to distinguish them from other neurological disorders. CLICK TO REVIEW
Gut microbiome alterations in Parkinson disease (PD) have been reported repeatedly, but their functional relevance remains unclear. Fecal metabolomics, which provide a functional readout of microbial activity, have scarcely been investigated. We investigated fecal microbiome and metabolome alterations in PD, and their clinical relevance. CLICK TO REVIEW Additional article review (click to review)
A hallmark of Parkinson’s disease (PD) is the formation of Lewy bodies in the brain. Lewy bodies are rich in the aggregated form of misfolded α-Synuclein (α-Syn). The brain from PD patients can only be analysed after post-mortem, limiting the diagnosis of PD to the manifestation of motor symptoms. In PD patients and animal models
In this review, we briefly summarize recent findings and analyze the application of molecular metabolomics in familial and sporadic PD from genetic mutations, mitochondrial dysfunction, and dysbacteriosis. We also review metabolic biomarkers to assess the functional stage and improve therapeutic strategies to postpone or hinder the disease progression. CLICK TO REVIEW
Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease Read More »